RhumbLine Advisers’s Thorne Healthtech, Inc. Common Stock THRN Stock Holding History

RhumbLine Advisers’s Portfolio THRN Stock Details THRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-18,315	Closed	-$187K	–	4318
2023 Q3	$187K	Buy	18,315 +593	+3%	+$4.51K	﹤0.01%	3197
2023 Q2	$83.3K	Buy	17,722 +281	+2%	+$1.29K	﹤0.01%	3566
2023 Q1	$81K	Buy	17,441 +716	+4%	+$3.15K	﹤0.01%	2880
2022 Q4	$61K	Buy	16,725 +243	+1%	+$1.08K	﹤0.01%	2947
2022 Q3	$78K	Buy	16,482 +1,222	+8%	+$6.14K	﹤0.01%	3023
2022 Q2	$74K	Buy	+15,260	New	+$92.8K	﹤0.01%	3046

RhumbLine Advisers's THRN Position: Q4 2023 in Review

RhumbLine Advisers sold out of Thorne Healthtech, Inc. Common Stock (THRN) in Q4 2023, closing a stake of 18,315 shares — an estimated $187K sold.

RhumbLine Advisers first reported a position in THRN in Q2 2022 and held it in 6 quarters. The position peaked at $187K in Q3 2023. 0 funds tracked by Wall St. Rank hold THRN as of Q4 2023.

RhumbLine Advisers reported no remaining Thorne Healthtech, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
RhumbLine Advisers sold 18,315 Thorne Healthtech, Inc. Common Stock shares in Q4 2023, an estimated $187K.
RhumbLine Advisers first reported a position in Thorne Healthtech, Inc. Common Stock in Q2 2022 and held it in 6 quarters.
RhumbLine Advisers's Thorne Healthtech, Inc. Common Stock position peaked at $187K in Q3 2023.
0 funds tracked by Wall St. Rank held Thorne Healthtech, Inc. Common Stock as of Q4 2023.

Based on RhumbLine Advisers's 13F filing for Q4 2023, filed 8 Feb 2024.